AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 16.99 |
Market Cap | 525.18M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -5.52 |
PE Ratio (ttm) | -3.11 |
Forward PE | n/a |
Analyst | Hold |
Ask | 18.1 |
Volume | 292,791 |
Avg. Volume (20D) | 246,313 |
Open | 18.04 |
Previous Close | 17.94 |
Day's Range | 16.88 - 18.04 |
52-Week Range | 16.56 - 27.56 |
Beta | undefined |
About FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children i...
Analyst Forecast
According to 1 analyst ratings, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is $22, which is an increase of 28.13% from the latest price.
Next Earnings Release
Analysts project revenue of $75.39M, reflecting a 6.93% YoY growth and earnings per share of -0.37, making a -232.14% decrease YoY.
2 months ago · businesswire.com
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...